Daiichi's Pexidartinib Likely Needs REMS For Liver Safety Concerns

Cancer cells on scientific background.3d illustration
Daiichi Sankyo's pexidartinib showed a statistically significant improvement in overall response rate in TCGT patients compared to placebo. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers